{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:40:56Z","timestamp":1761237656138,"version":"3.37.3"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1124\/jpet.109.157800","type":"journal-article","created":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T04:13:52Z","timestamp":1250655232000},"page":"627-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic-Pharmacodynamic and Response Sensitization Modeling of the Intraocular Pressure-Lowering Effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270)"],"prefix":"10.1016","volume":"331","author":[{"given":"Kenneth T.","family":"Luu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Prasanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathie","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Fortner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Vicini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.109.157800_bib1","doi-asserted-by":"crossref","unstructured":"Audren F, Tod M, Massin P, Benosman R, Haouchine B, Erginay A, Caulin C, Gaudric A, and Bergmann JF (2004) Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 45:3435\u20133441.","DOI":"10.1167\/iovs.03-1110"},{"key":"10.1124\/jpet.109.157800_bib2","unstructured":"Bauer RJ and Guzy S (2004) Monte Carlo Parametric Expectation Maximization (MCPEM) Method for Analyzing Population Pharmacokinetic\/Pharmacodynamic (PK\/PD) Data, Kluwer Academic Publishers, Boston, MA."},{"key":"10.1124\/jpet.109.157800_bib3","doi-asserted-by":"crossref","unstructured":"Calissendorff B, Sj\u00f6quist B, H\u00f6gberg G, and Grunge-Lowerud A (2002) Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther 18:127\u2013131.","DOI":"10.1089\/108076802317373888"},{"key":"10.1124\/jpet.109.157800_bib4","doi-asserted-by":"crossref","unstructured":"Chen CL, Gelatt KN, and Gum GG (1980) Serum hydrocortisone (cortisol) values in glaucomatous and normotensive Beagles. Am J Vet Res 41:1516\u20131518.","DOI":"10.2460\/ajvr.1980.41.09.1516"},{"key":"10.1124\/jpet.109.157800_bib5","doi-asserted-by":"crossref","unstructured":"Dayneka NL, Garg V, and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457\u2013478.","DOI":"10.1007\/BF01061691"},{"key":"10.1124\/jpet.109.157800_bib6","doi-asserted-by":"crossref","unstructured":"Fujino H, West KA, and Regan JW (2002) Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem 277:2614\u20132619.","DOI":"10.1074\/jbc.M109440200"},{"key":"10.1124\/jpet.109.157800_bib7","doi-asserted-by":"crossref","unstructured":"Fujino H, Xu W, and Regan JW (2003) Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 278:12151\u201312156.","DOI":"10.1074\/jbc.M212665200"},{"key":"10.1124\/jpet.109.157800_bib8","doi-asserted-by":"crossref","unstructured":"Gabrielsson J and Peletier LA (2007) A nonlinear feedback model capturing different patterns of tolerance and rebound. Eur J Pharm Sci 32:85\u2013104.","DOI":"10.1016\/j.ejps.2007.06.001"},{"key":"10.1124\/jpet.109.157800_bib9","unstructured":"Gabrielsson J and Weiner D (2000) Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications, 3rd ed., Swedish Pharmaceutical Press, Stockholm, Sweden."},{"key":"10.1124\/jpet.109.157800_bib10","doi-asserted-by":"crossref","unstructured":"Gupta SK, Agarwal R, Galpalli ND, Srivastava S, Agrawal SS, and Saxena R (2007) Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma. Methods Find Exp Clin Pharmacol 29:665\u2013671.","DOI":"10.1358\/mf.2007.29.10.1147765"},{"key":"10.1124\/jpet.109.157800_bib11","doi-asserted-by":"crossref","unstructured":"Ke HZ, Crawford DT, Qi H, Simmons HA, Owen TA, Paralkar VM, Li M, Lu B, Grasser WA, Cameron KO, et al.. (2006) A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats. J Bone Miner Res 21:565\u2013575.","DOI":"10.1359\/jbmr.051110"},{"key":"10.1124\/jpet.109.157800_bib12","doi-asserted-by":"crossref","unstructured":"Larsson LI, Mishima HK, Takamatsu M, Orzalesi N, and Rossetti L (2002) The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol 47 (Suppl 1):S90\u2013S96.","DOI":"10.1016\/S0039-6257(02)00296-5"},{"key":"10.1124\/jpet.109.157800_bib13","doi-asserted-by":"crossref","unstructured":"Lavielle M and Mentr\u00e9 F (2007) Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 34:229\u2013249.","DOI":"10.1007\/s10928-006-9043-z"},{"key":"10.1124\/jpet.109.157800_bib14","doi-asserted-by":"crossref","unstructured":"Oh C, Saville BA, Cheng YL, and Rootman DS (1995) A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits. Pharm Res 12:433\u2013437.","DOI":"10.1023\/A:1016268922035"},{"key":"10.1124\/jpet.109.157800_bib15","doi-asserted-by":"crossref","unstructured":"Ohtori R, Sato H, Fukuda S, Ueda T, Koide R, Kanda Y, Kiuchi Y, and Oguchi K (1998) Pharmacokinetics of topical beta-adrenergic antagonists in rabbit aqueous humor evaluated with the microdialysis method. Exp Eye Res 66:487\u2013494.","DOI":"10.1006\/exer.1997.0448"},{"key":"10.1124\/jpet.109.157800_bib16","unstructured":"Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, and Autelitano A (2000) Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 41:2566\u20132573."},{"key":"10.1124\/jpet.109.157800_bib17","doi-asserted-by":"crossref","unstructured":"Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, and Stupp R (2004) Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10:3728\u20133736.","DOI":"10.1158\/1078-0432.CCR-03-0807"},{"key":"10.1124\/jpet.109.157800_bib18","doi-asserted-by":"crossref","unstructured":"Prasanna G, Fortner J, Xiang C, Zhang E, Carreiro S, Anderson S, Sartnurak S, Wu G, Gukasyan H, Niesman M, et al.. (2009) Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Exp Eye Res DOI: 10.1016\/j.exer.2009.05.002.","DOI":"10.1016\/j.exer.2009.05.002"},{"key":"10.1124\/jpet.109.157800_bib19","doi-asserted-by":"crossref","unstructured":"Regan JW (2003) EP2 and EP4 prostanoid receptor signaling. Life Sci 74:143\u2013153.","DOI":"10.1016\/j.lfs.2003.09.031"},{"key":"10.1124\/jpet.109.157800_bib20","doi-asserted-by":"crossref","unstructured":"Rivera JL, Bell NP, and Feldman RM (2008) Risk factors for primary open angle glaucoma progression: what we know and what we need to know. Curr Opin Ophthalmol 19:102\u2013106.","DOI":"10.1097\/ICU.0b013e3282f493b3"},{"key":"10.1124\/jpet.109.157800_bib21","doi-asserted-by":"crossref","unstructured":"Sakanaka K, Kawazu K, Tomonari M, Kitahara T, Nakashima M, Kawakami S, Nishida K, Nakamura J, and Sasaki H (2004) Ocular pharmacokinetic\/pharmacodynamic modeling for bunazosin after instillation into rabbits. Pharm Res 21:770\u2013776.","DOI":"10.1023\/B:PHAM.0000026426.20012.36"},{"key":"10.1124\/jpet.109.157800_bib22","doi-asserted-by":"crossref","unstructured":"Sharma A and Jusko WJ (1996) Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 24:611\u2013635.","DOI":"10.1007\/BF02353483"},{"key":"10.1124\/jpet.109.157800_bib23","unstructured":"Sj\u00f6quist B, Basu S, Byding P, Bergh K, and Stjernschantz J (1998) The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Dispos 26:745\u2013754."},{"key":"10.1124\/jpet.109.157800_bib24","doi-asserted-by":"crossref","unstructured":"Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131\u20131135.","DOI":"10.1016\/j.addr.2006.07.027"},{"key":"10.1124\/jpet.109.157800_bib25","doi-asserted-by":"crossref","unstructured":"Wakelkamp M, Alv\u00e1n G, Gabrielsson J, and Paintaud G (1996) Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 60:75\u201388.","DOI":"10.1016\/S0009-9236(96)90170-8"},{"key":"10.1124\/jpet.109.157800_bib26","doi-asserted-by":"crossref","unstructured":"Yagci R, Ers\u00f6z I, Aydin B, Beyaz E, G\u00fcrel A, Durmu\u00b0 M, and Duman S (2007) Aqueous humor and serum concentration of hydroxyproline in pseudoexfoliation syndrome. J Glaucoma 16:225\u2013229.","DOI":"10.1097\/IJG.0b013e31802dfc46"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524386719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524386719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.109.157800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T01:38:44Z","timestamp":1740015524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524386719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0022356524386719"],"URL":"https:\/\/doi.org\/10.1124\/jpet.109.157800","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic-Pharmacodynamic and Response Sensitization Modeling of the Intraocular Pressure-Lowering Effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.109.157800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}